MoonLake Immunotherapeutics (MLTX) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

MoonLake Immunotherapeutics

MLTX

NASDAQ

Unprofitable

Unprofitable

3B

Biotechnology

Next Earning date - 06 Mar 2025

3B

Biotechnology

Next Earning date - 06 Mar 2025

46.81USD

2.70 ( 6.12%)

After-hours 46.88$

0.07 (0.14%)

Market Closed (as of Feb 05, 17:32 EDT)

Relative Strenght

22

Volume Buzz

-59%

Earning Acce

No

Dist 52w H.

28%

Quote Panel

Updated February 6, 2025

1W 2.44 % 1M -6.17 % 3M -7.03 % 1Y -21.37 %

Key Metrics

Market Cap
2.97B
Shares Outstanding
63.06M
Share in Float
52.72M
Dividende
0

Earning Date
06 Mar 2025
Price Target
47.11
Average Volume
319406
Beta
1.278

Range
37.55-64.98
Industry
Biotechnology
Website
https://www.moonlaketx.com
Sector
Healthcare

Fundamentals

Relative Strength

MLTX

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q4.22

N/A

-0.31
vs NA

Q1.23

N/A

-0.23
vs -0.43

Q2.23

N/A

-0.23
vs -0.34

Q3.23

N/A

-0.18
vs -0.27

Q4.23

N/A

-0.12
vs -0.31

Q1.24

N/A

-0.22
vs -0.23

Q2.24

N/A

-0.39
vs -0.23

Q3.24

N/A

-0.56
vs -0.18

Q4.24

N/A

-0.62
vs -0.12

Q1.25

N/A

-0.64
vs -0.22

Sales Growth

YoY

Current

Estimates

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

19.7K vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Q3.24

NA

NA vs NA

Return on Equity

QoQ

Q4.22

-4%

-0.04
vs -0.27

Q1.23

-29%

-0.29
vs -0.04

Q2.23

-2%

-0.02
vs -0.29

Q3.23

-2%

-0.02
vs -0.02

Q4.23

-2%

-0.02
vs -0.02

Q1.24

-3%

-0.03
vs -0.02

Q2.24

-5%

-0.05
vs -0.03

Q3.24

-7%

-0.07
vs -0.05

Institutionnal Ownership

QoQ

Q4.22

33

33
vs 24

38%

Q1.23

43

43
vs 33

30%

Q2.23

84

84
vs 43

95%

Q3.23

132

132
vs 84

57%

Q4.23

148

148
vs 132

12%

Q1.24

133

133
vs 148

-10%

Q2.24

119

119
vs 133

-11%

Q3.24

116

116
vs 119

-3%

Earnings Growth

Latest News

MLTX

globenewswire.com

7 hours ago

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

MLTX

globenewswire.com

7 hours ago

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MLTX

globenewswire.com

8 hours ago

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MLTX

seekingalpha.com

8 hours ago

MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion

MLTX

seekingalpha.com

14 hours ago

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

MLTX

seekingalpha.com

18 hours ago

MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon